Full Press Release Details
- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET
PASADENA, Calif.--(BUSINESS WIRE)--$arwr--Arrowhead Pharmaceuticals, Inc.(NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026. The Company is hosting a conference call today, May 7, 2026, at 4:30 p.m. ET to discuss the results.
“Arrowhead continues to show strong execution in meeting and exceeding our commercial, R&D, and corporate goals. The company is on extremely strong footing to continue to drive growth in the near-term with numerous opportunities to create long-term shareholder value,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead Pharmaceuticals. “We remain focused on a few key areas as being critical sources of sustainable growth for Arrowhead, and we have made tangible advancements across these areas. These include: strengthening our commercial presence to bring REDEMPLO® and potentially other cardiometabolic products in the future to the many patients and physicians who need it; continuing to deliver best-in-class in discovery, development, and regulatory capabilities in support of a deep pipeline of RNAi therapeutics capable of silencing genes expressed throughout the body to treat various diseases; and, being strategic and disciplined around pipeline, portfolio, and financial management.”
Key REDEMPLO® Commercial Events
Key R&D Events
Key Corporate Events
Webcast and Conference Call and Details
Investors may access a live audio webcast on theEvents and Presentationspage under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register athttps://register-conf.media-server.com/register/BI94a3f6754bd3471e8e895704fb645ee5. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
Selected Fiscal 2026 Second Quarter Financial Results
| ARROWHEAD PHARMACEUTICALS, INC.CONSOLIDATED CONDENSED FINANCIAL INFORMATION(in thousands, except per share amounts) | |||||||
| Three months Ended March 31, | |||||||
| OPERATING SUMMARY | 2026 | 2025 | |||||
| Revenue | $ | 73,737 | $ | 542,709 | |||
| Operating Expenses: | |||||||
| Research and development | 173,253 | 133,102 | |||||
| General and administrative expenses | 41,744 | 28,405 | |||||
| Total operating expenses | 214,997 | 161,507 | |||||
| Operating (loss) income | (141,260 | ) | 381,202 | ||||
| Total other income (expense) | 3,695 | (11,586 | ) | ||||
| (Loss) income before income tax expense and noncontrolling interest | (137,565 | ) | 369,616 | ||||
| Income tax expense | 7 | 1,753 | |||||
| Net (loss) income including noncontrolling interest | (137,572 | ) | 367,863 | ||||
| Net loss attributable to noncontrolling interest, net of tax | (4,840 | ) | (2,582 | ) | |||
| Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc. | (132,732 | ) | 370,445 | ||||
| Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc. - Diluted | $ | (0.93 | ) | $ | 2.75 | ||
| Weighted-average shares used in calculating - Diluted | 142,417 | 134,484 | |||||
| March 31, | September 30, | ||||||
| 2026 | 2025 | ||||||
| FINANCIAL POSITION SUMMARY | (unaudited) | ||||||
| Cash, cash equivalents and restricted cash | $ | 188,517 | $ | 226,548 | |||
| Available-for-sale securities, at fair value and short-term investments | 1,595,574 | 692,818 | |||||
| Total cash resources (Cash, cash equivalents and restricted cash and Available-for-sale securities, at fair value and short-term investments) | 1,784,091 | 919,366 | |||||
| Other current and long-term assets | 484,174 | 465,929 | |||||
| Total Assets | $ | 2,268,265 | $ | 1,385,295 | |||
| Liability related to the sale of future royalties | $ | 383,829 | $ | 367,397 | |||
| Credit Facility | 199,639 | 254,883 | |||||
| Deferred revenue | 157,158 | 2,399 | |||||
| Convertible notes, net | 681,940 | - | |||||
| Other liabilities | 246,783 | 257,200 | |||||
| Total Liabilities | $ | 1,669,349 | $ | 881,879 | |||
| Total Arrowhead Pharmaceuticals, Inc. Stockholders' Equity | 613,977 | 466,052 | |||||
| Noncontrolling Interest | (15,061 | ) | 37,364 | ||||
| Total Noncontrolling Interest and Stockholders' Equity | $ | 598,916 | $ | 503,416 | |||
| Total Liabilities, Noncontrolling Interest and Stockholders' Equity | $ | 2,268,265 | $ | 1,385,295 | |||
| Shares Outstanding | 140,571 | 135,702 |
About REDEMPLO®(plozasiran)
REDEMPLO (plozasiran) is approved by the U.S. Food and Drug Administration as an adjunct to diet to reduce triglycerides in adults with Familial Chylomicronemia Syndrome (FCS). REDEMPLO is an siRNA therapeutic designed to suppress the production of apoC-III, a protein produced in the liver that raises triglyceride levels by slowing their breakdown and clearance. By targeting apoC-III with sustained silencing, REDEMPLO delivers significant reductions in triglyceride levels. REDEMPLO is the first and only siRNA FDA-approved treatment studied in both genetically confirmed and clinically diagnosed patients living with FCS.
For more information about REDEMPLO, visitOur Medicines.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
None.
ADVERSE REACTIONS
Most common adverse reactions in REDEMPLO treated patients (incidence ≥10% of patients treated with REDEMPLO and >5% more frequently than with placebo) are hyperglycemia, headache, nausea, and injection site reaction.
Please see full U.S.Prescribing Informationfor REDEMPLO®.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a commercial-stage pharmaceutical company developing medicines that treat intractable diseases by silencing the genes that cause them, harnessing the natural RNA interference (RNAi) mechanism. The company has built a broad portfolio of clinical and commercial RNAi therapeutics through its industry-leading targeted RNAi molecule (TRiM™) platform, which can precisely silence genes in a wide range of cell types, including liver, lung, muscle, adipose, and central nervous system tissue. At Arrowhead, we rapidly advance potential best- and first-in-class RNAi treatments for diseases with significant unmet medical need, because every day matters to the patients we serve.
For more information, please visitwww.arrowheadpharma.com, or follow us on X (formerly Twitter) at@ArrowheadPharma,LinkedIn,Facebook, andInstagram. To be added to the Company's email list and receive news directly, please visithttp://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline, products or product candidate or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about our beliefs and expectations regarding the long-term impacts of REDEMPLO®(plozasiran) on patient health and the health care system; our beliefs and expectations regarding the pricing, value, or expected timing for availability of our drugs and drug candidates; and our believes and expectations around the potential uses and value of the TRiM™ platform. These statements are based upon our current expectations and speak only as of the date hereof. Actual results or outcomes may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties the safety and efficacy of our products and product candidates, pricing and reimbursement decisions related to our products, demand for our products, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.Vince Anzalone, CFA626-304-3400ir@arrowheadpharma.com
Investors:LifeSci Advisors, LLCBrian Ritchie212-915-2578britchie@lifesciadvisors.com
Media:LifeSci Communications, LLCKendy Guarinoni, Ph.D.724-910-9389kguarinoni@lifescicomms.com